Daphne Zohar, Chief Executive Officer and Director of Seaport Therapeutics, Inc. (NASDAQ:SPTX), filed a Form 4 on November 13, 2026, disclosing a transfer of 100,000 shares of Common Stock to a donor-advised fund on November 10, 2026.

Key Highlights

  • Reporting person: Daphne Zohar, Chief Executive Officer and Director of Seaport Therapeutics, Inc.
  • Transaction date: November 10, 2026
  • Transaction type: 100,000 shares of Common Stock transferred (transaction code G) to a donor-advised fund for no consideration, at a price of $0
  • Post-transaction ownership: 1,094,001 shares of Common Stock held directly following the reported transaction
  • No derivative securities: No derivative security transactions were reported in this filing
  • Filing signed: By Lana Gladstein, Attorney-in-Fact, on November 13, 2026

Zohar Daphne's Share Transfer to Donor-Advised Fund at Seaport Therapeutics

According to the filing, Daphne Zohar, who serves as both Chief Executive Officer and Director of Seaport Therapeutics, Inc., transferred 100,000 shares of Common Stock on November 10, 2026. The filing's footnote states: "On November 10, 2026, the Reporting Person transferred 100,000 shares of Common Stock to a donor-advised fund for no consideration." The transaction is coded as "G" in the filing, consistent with a gift or similar transfer, and the recorded price is $0.

Following the reported transaction, the filing discloses that Zohar directly beneficially owns 1,094,001 shares of Common Stock. No indirect ownership or derivative security positions were reported in connection with this filing. The form covers only non-derivative securities in Table I, with Table II showing no derivative transactions.

The Form 4 was filed on November 13, 2026, and was signed by Lana Gladstein as Attorney-in-Fact for the reporting person. The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1(c) plan, as that checkbox was not checked on the form.

What Was Disclosed

Daphne Zohar, CEO and Director of Seaport Therapeutics, disclosed a transfer of 100,000 shares of Common Stock to a donor-advised fund for no consideration on November 10, 2026, leaving her with direct beneficial ownership of 1,094,001 shares.